Coronary Atherosclerosis Evaluation by Arterial Wall MRI

动脉壁 MRI 评估冠状动脉粥样硬化

基本信息

  • 批准号:
    6967144
  • 负责人:
  • 金额:
    $ 72.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-08-01 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Direct and noninvasive visualization of the extent of coronary artery atherosclerosis is a major goal in the effort to assess coronary heart disease. Coronary artery calcium and carotid intima medial thickness are examples of surrogate markers of coronary atherosclerosis that attempt to non-invasively define the extent of coronary artery disease present. Coronary calcium in particular is a marker for coronary atherosclerotic burden but is a minor component of total plaque and is not present in early plaque. Coronary artery wall MRI is a new method to directly measure the thickness of the coronary artery wall, and is the only existing noninvasive test without ionizing radiation that can directly interrogate the coronary vasculature and provide a measure of disease burden at this early stage. Prior studies have shown increased coronary artery wall thickness is detected by MRI when no or minimal narrowing of the coronary artery lumen is present. Thus, this study proposes to assess the role of coronary artery wall thickness as a measure of early atherosclerotic disease using MRI, and 2) to determine the relationship of coronary artery wall thickness to both known risk and other noninvasive surrogate markers of atherosclerosis. This study will be performed within the context of the Multi-Ethnic Study of Atherosclerosis (MESA), an NHBLI prospective study of 6814 subjects without clinically manifest atherosclerotic disease. The underlying hypothesis of the MESA study is that the pathway from risk factors to clinical disease is through the development of subclinical disease. The MESA cohort is well characterized in terms of traditional risk factors and serologic markers for atherosclerotic disease. There is also phenotypic characterization of the cohort using carotid ultrasound, coronary calcium and MRI of the carotid and aortic wall. The specific aims of this application are to 1) determine the relationship between known risk factors for cardiovascular disease and coronary artery wall thickness, 2) determine the relationship between coronary artery wall thickness and coronary artery calcium and carotid wall thickness and 3) measure the progression of coronary artery wall thickness over time. The combination of direct coronary artery wall thickness measurement by MRI with the existing disease markers in MESA will be an effective way to assess the relationship of these markers to early pathologic changes in the coronary arterial bed. The ability to directly define the extent of coronary atherosclerosis at an early stage should lead to an improved understanding of coronary risk factors and their impact on atherosclerosis development.
描述(由申请人提供):冠状动脉粥样硬化程度的直接和无创可视化是评估冠心病的主要目标。冠状动脉钙和颈动脉内膜内侧厚度是冠状动脉粥样硬化的替代标志物,它们试图无创地确定冠状动脉疾病的范围。特别是冠状动脉钙是冠状动脉粥样硬化负荷的一个标志,但它是总斑块的一个次要组成部分,在早期斑块中不存在。冠状动脉壁MRI是一种直接测量冠状动脉壁厚度的新方法,是目前唯一一种无需电离辐射即可直接询问冠状动脉血管并在早期阶段提供疾病负担测量的无创检测方法。先前的研究表明,当冠状动脉管腔没有狭窄或只有很小的狭窄时,MRI可以检测到冠状动脉壁厚度增加。因此,本研究建议利用MRI评估冠状动脉壁厚度作为早期动脉粥样硬化疾病的测量指标的作用,以及2)确定冠状动脉壁厚度与已知风险和其他非侵入性动脉粥样硬化替代标志物的关系。本研究将在多民族动脉粥样硬化研究(MESA)的背景下进行,这是一项NHBLI前瞻性研究,共有6814名无临床表现的动脉粥样硬化疾病的受试者。MESA研究的基本假设是,从危险因素到临床疾病的途径是通过亚临床疾病的发展。MESA队列在动脉粥样硬化疾病的传统危险因素和血清学标志物方面具有很好的特征。通过颈动脉超声、冠状动脉钙化和颈动脉和主动脉壁MRI对该队列进行表型表征。该应用程序的具体目的是:1)确定已知心血管疾病危险因素与冠状动脉壁厚度之间的关系;2)确定冠状动脉壁厚度与冠状动脉钙和颈动脉壁厚度之间的关系;3)测量冠状动脉壁厚度随时间的变化。MRI直接测量冠状动脉壁厚与MESA中已有的疾病标志物相结合,将是评估这些标志物与冠状动脉床早期病变关系的有效方法。在早期阶段直接确定冠状动脉粥样硬化程度的能力将有助于提高对冠状动脉危险因素及其对动脉粥样硬化发展的影响的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID A. BLUEMKE其他文献

DAVID A. BLUEMKE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID A. BLUEMKE', 18)}}的其他基金

CORE--IMAGING
核心--成像
  • 批准号:
    8013844
  • 财政年份:
    2010
  • 资助金额:
    $ 72.95万
  • 项目类别:
CORE--IMAGING
核心--成像
  • 批准号:
    7394300
  • 财政年份:
    2007
  • 资助金额:
    $ 72.95万
  • 项目类别:
Coronary Atherosclerosis Evaluation by Arterial Wall MRI
动脉壁 MRI 评估冠状动脉粥样硬化
  • 批准号:
    7103482
  • 财政年份:
    2005
  • 资助金额:
    $ 72.95万
  • 项目类别:
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY
亚临床心血管疾病研究
  • 批准号:
    6359450
  • 财政年份:
    1999
  • 资助金额:
    $ 72.95万
  • 项目类别:
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY
亚临床心血管疾病研究
  • 批准号:
    6019931
  • 财政年份:
    1999
  • 资助金额:
    $ 72.95万
  • 项目类别:
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY
亚临床心血管疾病研究
  • 批准号:
    6354533
  • 财政年份:
    1999
  • 资助金额:
    $ 72.95万
  • 项目类别:
CORE--IMAGING
核心--成像
  • 批准号:
    7700619
  • 财政年份:
  • 资助金额:
    $ 72.95万
  • 项目类别:
CORE--IMAGING
核心--成像
  • 批准号:
    8212640
  • 财政年份:
  • 资助金额:
    $ 72.95万
  • 项目类别:
CORE--IMAGING
核心--成像
  • 批准号:
    7802260
  • 财政年份:
  • 资助金额:
    $ 72.95万
  • 项目类别:

相似海外基金

Identification of smooth muscle cell genes causal in atherosclerotic plaque stability and cardiovascular disease risk
鉴定导致动脉粥样硬化斑块稳定性和心血管疾病风险的平滑肌细胞基因
  • 批准号:
    10720225
  • 财政年份:
    2023
  • 资助金额:
    $ 72.95万
  • 项目类别:
Endothelial Cell Respiration in Atherosclerotic Plaque Erosion
动脉粥样硬化斑块糜烂中的内皮细胞呼吸
  • 批准号:
    10586227
  • 财政年份:
    2023
  • 资助金额:
    $ 72.95万
  • 项目类别:
Mechanistic registry to study whether infection with Corona Virus Disease 2019 (COVID-19) accelerates atherosclerotic plaque progression
研究 2019 年冠状病毒病 (COVID-19) 感染是否加速动脉粥样硬化斑块进展的机制登记
  • 批准号:
    10482402
  • 财政年份:
    2022
  • 资助金额:
    $ 72.95万
  • 项目类别:
Mechanistic registry to study whether infection with Corona Virus Disease 2019 (COVID-19) alters atherosclerotic plaque progression
研究 2019 年冠状病毒病 (COVID-19) 感染是否会改变动脉粥样硬化斑块进展的机制登记
  • 批准号:
    10280423
  • 财政年份:
    2021
  • 资助金额:
    $ 72.95万
  • 项目类别:
Coronary Atherosclerotic Plaque Vascularization Assessed by Computed Tomography
通过计算机断层扫描评估冠状动脉粥样硬化斑块血管化
  • 批准号:
    8278878
  • 财政年份:
    2012
  • 资助金额:
    $ 72.95万
  • 项目类别:
Coronary Atherosclerotic Plaque Vascularization Assessed by Computed Tomography
通过计算机断层扫描评估冠状动脉粥样硬化斑块血管化
  • 批准号:
    8445222
  • 财政年份:
    2012
  • 资助金额:
    $ 72.95万
  • 项目类别:
Quantification and Characterization of Coronary Atherosclerotic Plaque by CT
CT 冠状动脉粥样硬化斑块的定量和表征
  • 批准号:
    8399031
  • 财政年份:
    2011
  • 资助金额:
    $ 72.95万
  • 项目类别:
Quantification and Characterization of Coronary Atherosclerotic Plaque by CT
CT 冠状动脉粥样硬化斑块的定量和表征
  • 批准号:
    8044972
  • 财政年份:
    2011
  • 资助金额:
    $ 72.95万
  • 项目类别:
Quantification and Characterization of Coronary Atherosclerotic Plaque by CT
CT 冠状动脉粥样硬化斑块的定量和表征
  • 批准号:
    8790457
  • 财政年份:
    2011
  • 资助金额:
    $ 72.95万
  • 项目类别:
Quantification and Characterization of Coronary Atherosclerotic Plaque by CT
CT 冠状动脉粥样硬化斑块的定量和表征
  • 批准号:
    8213457
  • 财政年份:
    2011
  • 资助金额:
    $ 72.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了